This study is a phase 2a clinical trial testing the safety, tolerability, and efficacy of the investigational medication KAN-101.
KAN-101 targets the immune cells that drive celiac disease and leaves the otherwise healthy components of the immune system intact. KAN-101 acts by re-educating T cells, or tolerizing them, so they do not respond to gluten antigens.
This trial may be an option for you if you:
- Are 18-70 years old
- Have biopsy-confirmed celiac disease
- Currently follow a gluten-free diet
Learn more at Anokion.com/SynCeD.